课题基金 / 基金详情

Molecular Mechanisms of Atherogenesis in Diabetes

Molecular Mechanisms of Atherogenesis in Diabetes
糖尿病动脉粥样硬化形成的分子机制
批准号:
7548835
负责人:
JAY W HEINECKE
金额:
$41.54万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-08-01 至 2013-05-31
关键词:
3-chlorotyrosineATP-Binding Cassette TransportersAccountingAffectAmino Acid SubstitutionAmino AcidsAnimalsAnti-Inflammatory AgentsAnti-inflammatoryAntiatherogenicApolipoproteinsApolipoproteins AArteriesAtherosclerosisBiochemicalBiochemical MarkersBiochemical PathwayBiologicalBlood VesselsCause of DeathCell membraneCellsChemicalsCholesterolCholesterol HomeostasisClinical ResearchComplementComplications of Diabetes MellitusDevelopmentDiabetes MellitusDiabetic AngiopathiesDiabetic macrovascular diseaseDiabetic mouseEndothelial CellsEventFamilyFatty AcidsFoam CellsGenerationsGlucoseGoalsHemeproteinsHigh Density LipoproteinsHumanHydroxyl RadicalHyperglycemiaIn VitroIncidenceInsulin-Dependent Diabetes MellitusInvestigationIsotopesLesionLipidsLipoproteinsMass FragmentographyMass Spectrum AnalysisMediatingMembrane Transport ProteinsMetabolicMethionineMitochondriaModificationMolecularMusNADPH OxidaseNatural regenerationNon-Insulin-Dependent Diabetes MellitusNonesterified Fatty AcidsOperative Surgical ProceduresOxidative PhosphorylationPathogenesisPathway interactionsPatternPeroxidasePeroxidesPhospholipidsPhysiologicalPlasmaPolyunsaturated Fatty AcidsPopulationPreventive InterventionPrimatesPrincipal InvestigatorProcessProductionPropertyProtease InhibitorProteinsProteomicsReactionRelative (related person)ResearchResistanceRiskRisk FactorsRoleShotgunsSiteSystemTestingTissuesTransgenic MiceTyrosineWomanatherogenesiscarbonyl compoundcardiovascular disorder riskchlorinationdiabeticgenetic regulatory proteinglycemic controlhypercholesterolemiain vivomacrophagemacrovascular diseasemenmonocytemouse modelnon-diabeticnonhuman primatenoveloxidationparticleprogramssugartandem mass spectrometry

项目摘要

项目成果

JAY W HEINECKE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Both diabetic men and diabetic women are at greatly increased risk for atherosclerotic vascular disease. Although certain risk factors for atherosclerosis are frequently present in diabetics, they cannot adequately account for the greatly increased incidence of atherosclerosis associated with diabetes. One important contributor could be alterations in high-density lipoprotein (HDL), which normally protects against atherosclerosis by removing excess cholesterol from macrophage foam cells. In vitro and in vivo studies demonstrate that two ABC transporters, ABCA1 and ABCG1, promote efflux of cellular cholesterol and phospholipids from macrophages to HDL or its apolipoproteins. Thus, factors associated with the diabetic milieu that modify HDL and impair its ability to interact with ABCA1 and ABCG1 are likely to strongly influence atherogenesis. The many biochemical abnormalities that might modify HDL include elevated levels of glucose and free fatty acids, the metabolic hallmarks of diabetes. We have shown that polyunsaturated fatty acids (PUFAs) in concert with glucose or other reactive carbonyls generate an intermediate that resembles hydroxyl radical. Using a combination of gas chromatography and mass spectrometry, we detected the pattern of oxidized amino acids generated by this pathway in aortic tissue from hyperglycemic nonhuman primates. Another pathway implicated in human atherogenesis is myeloperoxidase, a heme protein expressed by macrophages in human vascular lesions. We recently found that levels of 3-chlorotyrosine, a specific marker for protein damage by myeloperoxidase, are markedly elevated in HDL isolated from atherosclerotic tissue of diabetic humans. Moreover, we showed that methionine oxidation and chlorination of a single tyrosine residue in apolipoprotein A-l, the major HDL protein, impairs the ability of apoA-l to remove cellular cholesterol by the ABCA1 pathway. We hypothesize that oxidative modifications of HDL impair cholesterol efflux from macrophages and are of central importance in the pathogenesis of diabetic vascular disease. Therefore, this research will determine whether the glucose-PUFA and myeloperoxidase pathways pathway trigger damage to HDL and promote plaque development. We will seek evidence for these pathways through complementary studies of (i) cultured human endothelial cells and monocyte/macrophages, (ii) mouse models, and (iii) HDL isolated from plasma and aortic tissue of control and diabetic humans. We believe it will be essential to understand the molecular mechanisms of artery wall damage in order to develop specific therapies against the devastating complications of diabetes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Apolipoprotein C3-loading of apolipoprotein B100 lipoproteins and cardiovascular disease in patients with type 1 diabetes
  • 批准号:
    10546500
  • 项目类别:
  • 资助金额:
    $82.39万
  • 财政年份:
    2022
  • 负责人:
    JAY W HEINECKE
  • 依托单位:
Apolipoprotein C3-loading of apolipoprotein B100 lipoproteins and cardiovascular disease in patients with type 1 diabetes
  • 批准号:
    10370044
  • 项目类别:
  • 资助金额:
    $86.23万
  • 财政年份:
    2022
  • 负责人:
    JAY W HEINECKE
  • 依托单位:
Project 4: Lipoproteins and CVD risk in diabetes
  • 批准号:
    10642754
  • 项目类别:
  • 资助金额:
    $44.32万
  • 财政年份:
    2020
  • 负责人:
    JAY W HEINECKE
  • 依托单位:
Project 4: Lipoproteins and CVD risk in diabetes
  • 批准号:
    10450864
  • 项目类别:
  • 资助金额:
    $43.47万
  • 财政年份:
    2020
  • 负责人:
    JAY W HEINECKE
  • 依托单位:
海外基金